Evolving concepts in Phase I and II Drug Development for Crohn's Disease.

Evolving concepts in Phase I and II Drug Development for Crohn's Disease.

The highest attrition rates during drug development programs occur at the proof of concept stage. Given the large number of molecules under development for Crohn's disease, a need exists to improve the efficiency of early drug development by fast-tracking promising agents and terminating ineffe...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Jairath, V, Levesque, B, Vande Casteele, N, Khanna, R, Mosli, M, Hindryckx, P, Travis, S, Duijvenstein, M, Rimola, J, Panes, J, D'Haens, G, Sandborn, W, Feagan, B
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	Oxford University Press 2016

Gelijkaardige items

Evolving concepts in phases I and II drug development for Crohn's Disease
door: Jairath, V, et al.
Gepubliceerd in: (2016)

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
door: Sandborn, W, et al.
Gepubliceerd in: (2016)

Placebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn's disease
door: Jairath, V, et al.
Gepubliceerd in: (2016)

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
door: D'Haens, G, et al.
Gepubliceerd in: (2009)

Biosimilars in IBD: hope or expectation?
door: Gecse, K, et al.
Gepubliceerd in: (2013)

Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.
door: Peyrin-Biroulet, L, et al.
Gepubliceerd in: (2012)

Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn’s disease: an IOIBD initiative
door: Danese, S, et al.
Gepubliceerd in: (2015)

Development of the Crohn's disease digestive damage score, the Lemann score.
door: Pariente, B, et al.
Gepubliceerd in: (2011)

Standardizing scoring conventions for Crohn’s disease endoscopy: An international RAND/UCLA appropriateness study
door: Khanna, R, et al.
Gepubliceerd in: (2023)

Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis
door: Samaan, MA, et al.
Gepubliceerd in: (2018)

Biologic Therapies: From Complexity to Clinical Practice in a Changing Environment
door: Remo Panaccione, et al.
Gepubliceerd in: (2015-12-01)

Biomarker correlation with endoscopic outcomes in patients with Crohn's disease: data from CALM
door: Reinisch, W, et al.
Gepubliceerd in: (2018)

Systematic review and meta-analysis: Prevalence, risk factors, and costs of aminosalicylate use in Crohn’s disease
door: Ma, C, et al.
Gepubliceerd in: (2018)

Placebo response and remission rates in Ulcerative Colitis clinical trials: Systematic review and meta-analysis
door: Jairath, V, et al.
Gepubliceerd in: (2015)

A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.
door: Gasche, C, et al.
Gepubliceerd in: (2000)

Central Endoscopy Reading in Inflammatory Bowel Diseases
door: Panés, J, et al.
Gepubliceerd in: (2016)

Characterization of Mucosal Lesions in Crohn's Disease Scored With Capsule Endoscopy: A Systematic Review
door: Miquel Marquès Camí, et al.
Gepubliceerd in: (2021-01-01)

Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis
door: Jairath, V, et al.
Gepubliceerd in: (2017)

Steroid-Dependent Crohn’s Disease
door: William J Sandborn
Gepubliceerd in: (2000-01-01)

Infliximab in the Treatment of Crohn’s Disease
door: Brian Feagan
Gepubliceerd in: (2000-01-01)

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
door: Van Assche, G, et al.
Gepubliceerd in: (2011)

Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease
door: Ariela K. Holmer, et al.
Gepubliceerd in: (2020-11-01)

A product review of vedolizumab in inflammatory bowel disease
door: Robert Battat, et al.
Gepubliceerd in: (2019-10-01)

“Dramatische taalvaardigheid” and how to remediate it - Developing and evaluating a remedial writing programme in a Dutch-medium secondary school
door: D'Haens, A
Gepubliceerd in: (2020)

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
door: Sandborn, W, et al.
Gepubliceerd in: (2015)

Differentiation of fibrotic and inflammatory component of Crohn’s disease-associated strictures
door: Jordi Rimola, et al.
Gepubliceerd in: (2020-04-01)

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
door: Colombel, J, et al.
Gepubliceerd in: (2017)

Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials.
door: Gottlieb, K, et al.
Gepubliceerd in: (2015)

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
door: Panaccione, R, et al.
Gepubliceerd in: (2019)

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.
door: Travis, S, et al.
Gepubliceerd in: (2006)

Linguistic strategies referring to politicians in the Spanish written press: an analysis of appositive constructions
door: An Vande Casteele
Gepubliceerd in: (2010-12-01)

Linguistic strategies referring to politicians in the Spanish written press: an analysis of appositive constructions
door: An Vande Casteele
Gepubliceerd in: (2011-04-01)

The missing “C”: Crohn's, colitis and coping
door: Turki AlAmeel, et al.
Gepubliceerd in: (2019-01-01)

The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis
door: Travis, S, et al.
Gepubliceerd in: (2013)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
door: Travis, S, et al.
Gepubliceerd in: (2014)

Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)
door: Vipul Jairath, et al.
Gepubliceerd in: (2022-04-01)

Budesonide MMX® for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis.
door: Lichtenstein, G, et al.
Gepubliceerd in: (2015)

Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis
door: Bryan Linggi, et al.
Gepubliceerd in: (2021-09-01)

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.
door: Mahadevan, U, et al.
Gepubliceerd in: (2011)

Sepsis: evolving concepts and challenges
door: R. Salomão, et al.
Gepubliceerd in: (2019-04-01)